Objective: To evaluate the efficacy and safety of nebulized IFN-αlb on viral infection of upper respiratory tract in children. Method: A randomized, open lable, parallel, controlled trial was performed. 163 children with viral upper respiratory tract infection were randomly allocated to experiment group ( n = 83 ) and control group ( n = 80 ). There were no differences on gender, age, height, and clinical manifestation of patients between two groups. Experiment group used interferon-1 alpha, control group used NS. Result: Experiment group compared with control group, There were fine effect in the aspects of pyretolysis and cold improving. There's significant difference between two groups. Conclusion: Interferon-1 alpha could be effectively and safety for respiratory virus infection of upper respiratory tract in children, and could easily reach oropharynx in high concentration and fewer adverse effects. A conception of treating common cold using interferon-1 alpha aerosol without injection as a first choice are proposed.%目的:临床观察和评估干扰素α1b雾化吸入治疗儿童上呼吸道病毒性感染的临床疗效及安全性.方法:采用随机、开放、平行对照方法,163例临床诊断为病毒性上呼吸道感染患儿,分为实验组83例,对照组80例,两组病例治疗前性别、年龄、身高、临床症状等差异无显著性;试验组干扰素α1b雾化吸入治疗,每次生理盐水20mL加干扰素α1b 20万单位,一日两次,对照组生理盐水20mL雾化吸入,每日两次.结果:实验组在退热、感冒症状改善方面与对照组比较,病程缩短,差异有显著性.结论:干扰素α1b雾化吸入疗效确切,药物直达口咽,起效迅速,不良反应小,可作为早期干预上呼吸道病毒感染的首选用药.
展开▼
